Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,806 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term imatinib therapy promotes bone formation in CML patients.
Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC. Fitter S, et al. Among authors: lynch k. Blood. 2008 Mar 1;111(5):2538-47. doi: 10.1182/blood-2007-07-104281. Epub 2007 Nov 27. Blood. 2008. PMID: 18042796 Free article.
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T. White DL, et al. Among authors: lynch k. Blood. 2007 Dec 1;110(12):4064-72. doi: 10.1182/blood-2007-06-093617. Epub 2007 Aug 30. Blood. 2007. PMID: 17761829 Free article. Clinical Trial.
Bisphosphonate infusions: patient preference, safety and clinic use.
Chern B, Joseph D, Joshua D, Pittman K, Richardson G, Schou M, Lowe S, Copeman M, De Abreu Lourenco R, Lynch K. Chern B, et al. Among authors: lynch k. Support Care Cancer. 2004 Jun;12(6):463-6. doi: 10.1007/s00520-004-0628-z. Epub 2004 Apr 16. Support Care Cancer. 2004. PMID: 15088136 Clinical Trial.
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer AP, Ma D, Seymour JF, Bradstock K, Joske D, Lynch K, Gathmann I, Hughes TP. Branford S, et al. Among authors: lynch k. Leukemia. 2003 Dec;17(12):2401-9. doi: 10.1038/sj.leu.2403158. Leukemia. 2003. PMID: 14523461 Clinical Trial.
Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, Matthews J, Turner S, Atkinson C, Tai KH, Gogna NK, Kenny L, Diamond T, Smart R, Rowan D, Moscato P, Vimieiro R, Woodfield R, Lynch K, Delahunt B, Murray J, D'Este C, McElduff P, Steigler A, Kautto A, Ball J. Denham JW, et al. Among authors: lynch k. BJU Int. 2014 Sep;114(3):344-53. doi: 10.1111/bju.12497. Epub 2014 Feb 11. BJU Int. 2014. PMID: 24512527 Clinical Trial.
1,806 results